CRLconf 0.85

molgramostim inhalation — CRL

$SVRA · Savara Inc · autoimmune pulmonary alveolar proteinosis

Event date

May 27, 2025

375 days ago

Sponsor runway

18 mo

$202.8M liquid

Evidence

“On May 27, 2025, Savara Inc. issued a press release announcing that it has received a refusal to file letter from the U.S. Food and Drug Administration for the Biologics License Application for molgramostim inhalation solution to treat patients with autoimmune pulmonary alveolar proteinosis.”

Source: 8-K filed 2025-05-27View on EDGAR ↗0001193125-25-126273

Comparable historical crls· last 5 years · same event type

No comparable historical outcomes in our database yet — backfill of past readouts arrives next ingestion cycle.

Recent insider activity· ±90 days

3 insiders · 3 buys · 0 sells

Buy

2025-06-20

Hawkins Richard J

Director

48,225 @ $2.04$99K

Buy

2025-05-29

McCracken Joseph S

Director

10,000 @ $2.08$21K

Buy

2025-03-31

RAMSAY DAVID A

Director

150,000 @ $2.77$416K

Date	Insider	Action	Shares	Price	Value
2025-06-20	Hawkins Richard JDirector	Buy	48,225	$2.04	$99K
2025-05-29	McCracken Joseph SDirector	Buy	10,000	$2.08	$21K
2025-03-31	RAMSAY DAVID ADirector	Buy	150,000	$2.77	$416K

← All catalysts for $SVRA